Comparative Pharmacology
Head-to-head clinical analysis: FUROSCIX versus FUROSEMIDE.
Head-to-head clinical analysis: FUROSCIX versus FUROSEMIDE.
FUROSCIX vs FUROSEMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.
None Documented
None Documented
Clinical Note
moderateFurosemide + Digoxin
"The risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin."
Clinical Note
moderateFurosemide + Digitoxin
"The risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin."
Clinical Note
moderateFurosemide + Deslanoside
"The risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside."
Clinical Note
moderateFurosemide + Acetyldigitoxin
Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (CrCl <30 mL/min) and 9-19 hours in anuria
0.5-2 hours (terminal); prolonged in renal impairment (up to 9-24 hours) and hepatic cirrhosis (up to 2-4 hours).
Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%)
Renal (50-80% unchanged; remainder as glucuronide metabolite); fecal (<2%).
Category C
Category A/B
Loop Diuretic
Loop Diuretic
"The risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin."